Connect with us

Emerging Markets

American Diversified Holdings Corp (OTCMKTS: ADHC) Major Run Northbound as Co Teases New Acquisition and Up List

Published

1 year ago

on

American Diversified Holdings Corp (OTCMKTS: ADHC) is rocketing up the charts making double digit gains both yesterday and today. The Company has published an annual roadmap which I have included below. The first thing on the roadmap was “pink current” which has been accomplished by the Company. ADHC now plans to up list to fully reporting OTCQB which requires a minimum bid price of $0.01. It also speaks of a CBD acquisition followed by a $100 million revenue acquisition announcement. ADHC management stated on twitter there would be a press release on Thursday, May 27. The Company has stated numerous times on twitter they are working with the TA on a share cancellation.  

On May 3 AHDC entered into a Joint Venture/Acquisition agreement with ROLLS CHOICE (TM). The agreement provides for ADHC to provide funding to ROLLS CHOICE. A royalty will be paid to ADHC from the gross sales of Rolls Choice line of cannabis related adhesive products. After a due diligence period and further research into the development of ROLLS CHOICE product line, the parties anticipate that ADHC will acquire all the assets of ROLLS CHOICE. Additionally, Allen Staines, the founder of ROLLS CHOICE will be responsible for all ADHC and Universal Wellness social media sites including Twitter and Instagram. ROLLS CHOICE has applied for a trademark with the USPTO under the application number 972978083. 

American Diversified Holdings Corp (OTCMKTS: ADHC) operating out of Del Mar, California is a publicly traded holding company trading under the ticker symbol (OTC-“ADHC”). Up until recently the Company owned several e commerce websites in the crypto and cannabis space. The Company’s mission is to bring natural health and wellness products to people around the world. Promising to deliver safe and tested products, that support vitality, longevity and overall well-being. 

In January ADHC announced the company has filed an amended complaint adding more allegations against Tourist Cruise and its CEO Xavier Massana aka (Xavier Joan Massana I Modrono) CEO Ace Capital, Sergio Bellosta Suarez, CEO of Promotional Networks and CEO of Indo Global Exchanges (“IGEX”), Miroslav Zecevic, of Mina Mar Marketing Group (“Mina Mar Group”), Mina Mar Corporation, and additional Spanish entities (among others) involving allegations of serious misconduct perpetrated against ADHC, a public company, Ernest B. Remo, and the ADHC shareholders. 

ADHC and Remo have amended their complaint, adding additional information and seeking additional relief from Zecevic’s improper interference with ADHC’s business relationship with a joint venture partner and CBD acquisition candidate. As detailed in the complaint, correspondence with the CEO of the acquisition candidate, Zecevic improperly threatened to add them to pending litigation after the announcement of the executed letter of intent. The amended complaint states that such actions interfered with ADHC’s business relationships causing significant financial harm. Additionally, the amended complaint identifies Xavier Massana, a principal of Tourist Cruise SL, as an individual who has a history of improper shares issuances and returning shares to issuing entities. Indeed, as reflected in various 8-K filings, in one such instance earlier in 2021, Massana returned tens of millions of shares in Mojo Data Solutions Inc. The amended complaint not only details Massana’s torrid past in having to return millions of shares, but doing so in 8-K filings where he (or his affiliated businesses), share the same address with Zecevic and Mina Mar Group. 

This legal action contains allegations of years of improper actions that have caused significant harm to ADHC shareholders. Setting forth claims of conversion and intentional interference with contract against Zecevic (among other claims), the complaint states, “In August and September 2019, Zecevic caused over 300 million ADHC shares to be issued to the Spanish entities. However, the monies that were paid for the shares were never received by ADHC. Instead of ensuring that ADHC would be paid for its shares, Zecevic arranged to have the monies paid directly to Mina Mar Corp., Zecevic’s own business. ADHC, then a Nevada corporation, received nothing for these substantial share issuances. In addition to directing payment to his company, Zecevic set the price for the shares issued to Tourist Cruise SL (one of the Spanish entities) at 10% of the then-current price as traded on the open market.” In support of these statements, the complaint attaches a purported “bank record from August 12, 2019 directing payment from Tourist Cruise SL to Mina Mar Corp. [not ADHC] for 62,500,000 ADHC shares.” 

https://twitter.com/ADHCMANAGEMENT/status/1529819967117398022

To Find out the inside Scoop on ADHC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ADHC

On May 3 AHDC entered into a Joint Venture/Acquisition agreement with ROLLS CHOICE (TM). The agreement provides for ADHC to provide funding to ROLLS CHOICE. A royalty will be paid to ADHC from the gross sales of Rolls Choice line of cannabis related adhesive products. After a due diligence period and further research into the development of ROLLS CHOICE product line, the parties anticipate that ADHC will acquire all the assets of ROLLS CHOICE. Additionally, Allen Staines, the founder of ROLLS CHOICE will be responsible for all ADHC and Universal Wellness social media sites including Twitter and Instagram. ROLLS CHOICE has applied for a trademark with the USPTO under the application number 972978083 

“I am very excited about joining Universal Wellness. The company provides a perfect match for growing the Cannabis Adhesive Glue Pen Product line, as well as the many other products I have under development, ” commented Allen Staines, of ROLLED CHOICE. 

ROLLED CHOICE (TM) has over 80,000 social media followers which will be introduced to Universal Wellness social media platforms. This relationship will establish a very strong presence providing brand awareness to potential customers and shareholders as the Universal Wellness/Rolls Choice business relationship develops and revenues grow. 

Rolls Choice ™ is a south California based manufacturer, distributer and ecommerce company selling an all-natural Adhesive Glue and application device. The Pens come in 1 ml, 2 ml and 100 pen packs. Rolls Choice has significant brand awareness in the cannabis industry and boasts over 80,000 followers on Twitter and Instagram. Over 12,000 adhesive pens have been manufactured and sold. The adhesive is made of Food Grade Premium ingredients. Rolls Choice Adhesive Pen is Flavorless, Colorless, Tasteless and Stainless. It is used to seal cannabis and tobacco rolled products including blunts, joints, cigars and hand rolled cigarettes in a sterile manner allowing for long lasting adhesive qualities. The proprietary brush tip pen is recommended for precision. RC sells direct to smoke shops, dispensaries and direct to consumers through its e-commerce site. Through the companies multi year history sales over 12,000 adhesive pens and been manufactured and sold by Rolls Choice. see (USPTO ROLLS CHOICE 97278083). In addition to the adhesive pen, RC has numerous other cannabis related products being developed that will be introduced as a result of this JV/Acquisition agreement. 

For More on ADHC Subscribe Right Now!

Currently trading at a $3.7 million market valuation ADHC OS is pretty much maxed out at 946,493,171 with AS set to 1 billion. Almost half of the Company’s OS is restricted shares leaving just 504,181,880 free trading shares. ADHC has just $62k in the treasury in investments and $2.8 million in liabilities, most of it owed by the Company’s current management and no convertible debt. ADHC is an exciting story developing in small caps; volume has picked up substantially in recent days as the stock has made double digit gains now two days in a row. There are a lot of rumors going around concerning some big players that I cannot mention here. The Company said on twitter today there is a PR coming tomorrow. We will be updating on ADHC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ADHC.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in ADHC either long or short and we have not been compensated for this article.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

3 days ago

on

May 31, 2023

By

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Emerging Markets

Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval

Published

2 weeks ago

on

May 21, 2023

By

Aemetis (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the EPA.

Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.

Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.

They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.

They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.

To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.

The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.

Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.

https://twitter.com/Theweedfarmer/status/1658946668052504576?s=20

Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?

The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.

The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.

The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies. 

The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.

We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Leopold Böttcher from Pixabay

Continue Reading

Emerging Markets

GSI Technology, Inc. (NASDAQ: GSIT): Pure AI Play Transforming Semiconductor Memory Solutions for Efficient AI Processing

Published

3 weeks ago

on

May 14, 2023

By

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12.

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12. This represents an impressive 137% increase; the volume has been off the hook. If you look at their historical chart, $GSIT had meager volume, sometimes as low as 300 shares traded in a day. If you do the math, that’s less than $500 worth of shares traded in a day – safe to say it was virtually illiquid.

So what happened, and what drove the stock to trade 50M shares with filings or news releases?

After an in-depth examination, GSI Technology, Inc. appears to have experienced a notable turning point in its market trajectory. The catalyst for this transformation was the company’s prominent feature on Fox News, triggering an exponential dissemination of information across various platforms. It is worth highlighting an intriguing phenomenon that tends to transpire in such circumstances: purchasing shares often induces a ripple effect, encouraging further buying activity.

With Fox News bringing the company into the spotlight and stimulating investor interest, a domino effect occurred among astute day traders who eagerly seized the opportunity to partake in this promising venture. Consequently, the trading volume for GSI Technology, Inc. skyrocketed to unprecedented levels, surpassing all previously recorded thresholds.

This surge in volume stands as a testament to the immense enthusiasm that enveloped the market as traders recognized the tremendous potential inherent in $GSIT. This collective enthusiasm resulted in an extraordinary demonstration of market engagement, reflecting a widespread acknowledgment of the company’s significance and the opportunities it presents.

https://twitter.com/SamanthaLaDuc/status/1657033207412293634?s=20

This development showcases the power of influential media coverage and underscores the intriguing dynamics that can arise when investor sentiment aligns with a compelling market narrative.

To Discover the Inside Scoop on GSIT, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Founded in 1995, GSI Technology Inc. has established itself as a prominent provider of semiconductor memory solutions. The company is focused on introducing new products that capitalize on its core strengths, which include radiation-hardened memory products for extreme environments and Gemini, an advanced processing unit (APU) designed to enhance performance in various artificial intelligence (AI) applications. Headquartered in Sunnyvale, California, GSI Technology operates sales offices in the Americas, Europe, and Asia.

GSI Technology is on the verge of reporting its earnings next week, and the company operates in the storage business, which supports the development of highly efficient AI chips. Traditionally, computing involves separate chips for storage and computation, necessitating frequent data exchange. This process incurs significant power consumption and presents scalability challenges.

To address these limitations, GSI Technology has developed a groundbreaking solution called In-memory processing. This innovation substantially reduces computation time from minutes to seconds, milliseconds, or even microseconds. Notably, it also significantly diminishes power consumption and overall cost of ownership. The key to this improvement lies in the massive parallel data processing offered by GSI’s technology, featuring two million-bit processors per chip compared to thousands found in standard graphic processing units (GPUs). Consequently, the system becomes more scalable, enabling efficient and accelerated AI processing.

By streamlining the computing process and integrating storage and computation on a single chip, GSI Technology aims to revolutionize AI processing. This approach offers notable benefits regarding power efficiency, computational speed, and scalability, making it an attractive solution for a wide range of AI applications.

In conclusion, GSI Technology, Inc. is poised to deliver innovative semiconductor memory solutions emphasizing AI chip development. The company aims to reduce computation time, power consumption, and total ownership cost through its In-memory processing technology while significantly improving scalability. With its upcoming earnings report, investors and industry observers will closely watch the company’s progress in the storage business and AI chip development.

We will update you on GSIT when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with GSIT.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.